ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Adjuvant <strong>Breast</strong>: HER2/neu Positive (High or Low Risk)Hormone Therapy:Nolvadex (Tamoxifen)Tamoxifen 20mg PO q D x 5 years>> J Natl <strong>Cancer</strong> Inst 91:1829-1846, 1999Aromatase Inhibitor (plus ovarian ablation for premenopausal women)Anastrozole 1mg PO q D x 5 yearsExemestane 25mg PO q D x 5 yearsLetrozole 2.5mg PO q D x 5 years>> J Clin Oncol 26:1059-1065, 2008Nolvadex (Tamoxifen) Followed by Aromatase InhibitorTamoxifen 20mg PO q DFollowed by one of the following AI’s:Anastrozole 1mg PO q DExemestane 25mg PO q DLetrozole 2.5mg PO q D>> J Natl <strong>Cancer</strong> Inst 2005; 97:1262-1271Zoladex (Goserelin)Goserelin 3.6 mg SQ q MonthNote: Ovarian suppression>> Lancet 369: 1711, 2007Chemotherapy:Adriamycin (Doxorubicin) Cytoxan (Cyclophosphamide) Followed by Taxol(Paclitaxel) Herceptin (Trastuzumab) EP=High; FN=10%-20%Doxorubicin 60mg/m 2 D1Cyclophosphamide 600mg/m 2 D1q 21 Day Cycle x 4 CyclesFollowed by:Paclitaxel 80mg/m 2 D1, D8, D15Trastuzumab 4mg/kg D1 (Cycle 1 only)2mg/kgD1, D8, D15q 21 Day Cycle x 4 CyclesThen continue:Trastuzumab 6mg/kg D1q 21 Day Cycle x 13 Cycles>> N Engl J Med 353:1673-1684, 2005Page 7 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language